Michael Richman

Founder at NextCure, Inc.

Michael Richman

Michael Richman

Founder at NextCure, Inc.

Overview
Career Highlights

MacroGenics, Inc.
Amplimmune, Inc.
NextCure, Inc.

RelSci Relationships

1576

Number of Boards

12

Birthday

1961

Age

59

Relationships
RelSci Relationships are individuals Michael Richman likely has professional access to. A relationship does not necessarily indicate a personal connection.

Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

Founder at NextCure, Inc.

Relationship likelihood: Strong

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

Chief Executive Officer, President & Director at Pieris Pharmaceuticals, Inc.

Relationship likelihood: Strong

General Partner at Canaan Management, Inc.

Relationship likelihood: Strong

Director at Codeco Corp.

Relationship likelihood: Strong

President at ICT Holdings LLC

Relationship likelihood: Strong

Partner at Lilly Asian Ventures

Relationship likelihood: Strong

Co-Founder at Madison Vaccines, Inc.

Relationship likelihood: Strong

Independence Chairman of the Board at Genvec Inc.

Relationship likelihood: Strong

Paths to Michael Richman
Potential Connections via
Relationship Science
You
Michael Richman
Founder at NextCure, Inc.
Education
M.S.B.A. International Business

San Francisco State University was established in 1899 as a teacher-training school. SF State has been known for its commitment to excellent teaching. Students work closely with senior professors and other instructors from freshman year through graduation. Trained in some of the finest institutions in the world, faculty members include winners of prestigious teaching awards, cutting-edge researchers, and professionals devoted to solving community problems.

B.S. Genetics & Molecular Biology

The University of California, Davis (also referred to as UCD, UC Davis, or Davis) is a public teaching and research university located in Davis, California just west of Sacramento. The campus covers 7,309 acres (2,958 ha), making it the largest within the 10 campus University of California system. UC Davis also has the third largest enrollment in the UC System after UCLA and UC Berkeley. The University of California, Davis campus is the largest campus in the UC system by land area, spanning 7,309 acres (2,957.8 ha) across two counties: Yolo and Solano. Though named after the City of Davis, the campus is technically located adjacent to the City of Davis in an unincorporated part of Yolo and Solano counties. The main campus is located 15 miles (24.1 km) west of Sacramento in the Sacramento Valley, part of California's Central Valley, and is adjacent to Interstate Highway 80. The Davis campus is the only school within the UC system with an airport, just west of main campus, and is one of two UC schools with its own fire department; the other being UC Santa Cruz. The campus is also conveniently located approximately an hour away from both San Francisco and the Napa Valley and two hours from Lake Tahoe. It is also one of only three schools in the University of California system, the others being UC Berkeley and UC Irvine, with a nuclear lab.

Career History
Founder
2015 - Current

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

President & Chief Executive Officer
2007 - 2015

Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD.

Chief Operating Officer & Executive Vice President
2002 - 2007

MacroGenics is a leader in the discovery and development of innovative medicinces that utilize our next generation antibody-based technologies. Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases. Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe. Our innovative product candidates leverage our fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms: Our Dual-Affinity Re-Targeting (DART™) platform enables us to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; Our Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells; and Our Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy.

Boards & Committees
Independent Director
2014 - Current

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Member, Board of Directors
Current

Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD.

Transactions
Details Hidden

NextCure, Inc. raised money in a private placement transaction

Details Hidden

NextCure, Inc. raised money in a private placement transaction

Details Hidden

MedImmune LLC, AstraZeneca Plc purchase Amplimmune, Inc. from InterWest Partners, LLC

Investments
Details Hidden

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michael Richman. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michael Richman's profile does not indicate a business or promotional relationship of any kind between RelSci and Michael Richman.